Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56993
Full metadata record
???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
---|---|---|
dc.contributor.advisor | 陳明汝(Ming-Ju Chen) | |
dc.contributor.author | Yi-Hsin Pai | en |
dc.contributor.author | 白憶欣 | zh_TW |
dc.date.accessioned | 2021-06-16T06:32:33Z | - |
dc.date.available | 2019-08-11 | |
dc.date.copyright | 2014-08-11 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-05 | |
dc.identifier.citation | 林雅婷。2011。開發潛力益生乳酸菌作為飼料添加物。碩士論文。國立臺灣大學動物科學技術學系。
郭怡孜。2006。應用最適化方法開發具隔熱性益生菌微膠囊。碩士論文。國立臺灣大學動物科學技術學系。 Adijiang, A., and T. Niwa. 2010. An oral sorbent, AST-120, increases Klotho expression and inhibits cell senescence in the kidney of uremic rats. Am. J. Nephrol. 31(2): 160-164. Aeschlimann, A., and U. von Stockar. 1990. The effect of yeast extract supplementation on the production of lactic acid from whey permeate by Lactobacillus helveticus. Appl. Microbiol. Biotechnol. 32(4): 398-402. Akizawa, T., Y. Asano, S. Morita, T. Wakita, Y. Onishi, S. Fukuhara, F. Gejyo, S. Matsuo, N. Yorioka, and K. Kurokawa. 2009. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am. J. Kidney Dis. 54: 459-467. Andrew, S. L., J. Coresh, E. Balk, A. T. Kausz, A. Levin, M. W. Steffes, R. J. Hogg, R. D. Perrone, J. Lau, and G. Eknoyan. 2003. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification and stratification . Ann. Intern. Med. 139: 137-147. Arany, I., and R. L. Safirstein. 2003. Cisplatin nephrotoxicity. Semin. Nephrol. 23(5): 460-464. Ateşşahin, A., A. O. Ceribaşi, A. Yuce, O. Bulmus, and G. Cikim. 2007. Role of ellagic acid against cisplatin-induced nephrotoxicity and oxidative stress in rats. Basic Clin. Pharmacol. Toxicol. 100(2): 121-126. Barreto, F. C., D. V. Barreto, S. Liabeuf, N. Meert, G. Glorieux, M. Temmar, G. Choukroun, R. Vanholder, and Z. A. Massy. 2009. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol. 4: 1551-1558. Benedetti, G., L. Fredriksson, B. Herpers, J. Meerman, B. van de Water, and M. de Graauw. 2013. TNF-α-mediated NF-κB survival signaling impairment by cisplatin enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells. Biochem. Pharmacol. 85(2): 274-286. Box, G. E. P., and K. B. Wilson. 1951. On the experimental attainment of optimum conditions. 8(1): 1-45 Brunet, P., B. Gondouin, A. Duval-Sabatier, L. Dou, C. Cerini, F. Dignat-George, N. Jourde-Chiche, A. Argiles, and S. Burtey. 2011. Does uremia cause vascular dysfunction? Kidney Blood Press Res. 34(4):284-90. Campieri, C., M. Campieri, V. Bertuzzi, E. Swennen, D. Matteuzzi, S. Stefoni, F. Pirovano, C. Centi, S. Ulisse, G. Famularo, and S. C. De. 2001. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int. 60: 1097-1105. Cerning, J., C. Bouillanne, M. Landon, and M. Desmazeaud. 1992. Isolation and characterization of exopolysaccharides from slime-forming mesophilic lactic acid bacteria. J. Dairy Sci. 75(3): 692-699. Champagne, C. P., H. Gaudreau, and J. Conway. 2003. Effect of the production or use of mixtures of bakers' or brewers' yeast extraction their ability to promote growth of Lactobacilli and pediococci. Electron. J. Biotechn. 6(3): 1-13. Chapman, C. M., G. R. Gibson, and I. Rowland. 2011. Health benefits of probiotics: are mixtures more effective than single strains? Eur. J. Nutr. 50: 1-17. Chapman, C. M., G. R. Gibson, and I. Rowland. 2012. In vitro evaluation of single- and multi-strain probiotics: Inter-species inhibition between probiotic strains, and inhibition of pathogens. Anaerobe. 18: 405-413. Cheilas, T., T. Stoupis, P. Christakopoulos, P. Katapodis, D. Mamma, D. G. Hatzinikolaou, D. Kekos, and B. J. Macris. 2000. Hemicellulolytic activity of Fusarium oxysporum grown on sugar beet pulp. Production of extracellular arabinase. Process Biochem. 35: 557-561. Collado, M. C., E. Isolauri, and S. Salminen, 2008. Specific probiotic strains and their combinations counteract adhesion of Enterobacter sakazakii to intestinal mucus. FEMS Microbiol. 285: 58-64. Coresh, J., B. C. Astor, T. Greene, G. Eknoyan, and A. S. Levey. 2003. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 41: 1-12. de Man, J. C., M. Rogosa, and M. E. Sharpe. 1960. A medium for the cultivation of Lactobacilli. J. Appl. Bact. 23: 130-135. de Moreno de LeBlanca, A., S. Chavesa, E. Carmuegac, R. Weilld, J. Anto’ inee, and N. Gabriela Perdigo’. 2008. Effect of long-term continuous consumption of fermented milk containing probiotic bacteria on mucosal immunity and the activity of peritoneal macrophages. Immunobiology. 213: 97-108. Duchmann, R., I. Kaiser, E. Hermann, W. Mayet, K. Ewe, and K. H. Meyer zum Buschenfelde. 1995. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin. Exp. Immunol. 102: 104-108. Evenepoel, P., B. K. Meijers, B. R. Bammens, and K. Verbeke. 2009. Uremic toxins originating from colonic microbial metabolism. Kidney Int. Suppl. 114: S12-S19. Fujii, H., K. Nakai, and M. Fukagawa. 2011. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. Ther. Apher. Dial. 15(2): 125-128. Fuller, R. 1989. Probiotics in man and animals. J. Appl. Bacteriol. 66:365-378. Gaon, D., C. Garmendia, N. O. Murrielo, A. de Cucco Games, A. Cerchio, and R. Quintas. 2002. Effect of Lactobacillus strains (L. casei and L. acidophilus Cerela) on bacterial overgrowth related chronic diarrhea. Medicina. 62:159-163. Gautier, J. C., B. Riefke, J. Walter, P. Kurth, L. Mylecraine, V. Guilpin, N. Barlow, T. Gury, D. Hoffman, D. Ennulat, K. Schuster, E. Harpur, and S. Pettit. 2010. Evaluation of novel biomarkers of nephrotoxicity in two strains of rat treated with cisplatin. Toxicologic. Pathol. 38: 943-956. Goldfarb, D.S., F. Modersitzki, and J. R. Asplin. 2007. A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin. J. Am. Soc. Nephrol. 2: 745-749. Gomathi, S., P. Sasikumar, K. Anbazhagan, S. Sasikumar, M. Kavitha, M. S. Selvi, and G. S. Selvam. 2014. Screening of indigenous oxalate degrading lactic acid bacteria from human faeces and South Indian fermented foods: assessment of probiotic potential. Sci. World. J. 648059. Hamon, E., P. Horvatovich, E. Izquierdo, F. Bringel, E. Marchioni, D. Aoude-Werner, and S. 2011. Ennahar. Comparative proteomic analysis of Lactobacillus plantarum for the identification of key proteins in bile tolerance. BMC Microbiol. 11:63. Han, W. K., and Bonventre, J. V. 2004. Biologic markers for the early detection of acute kidney injury. Curr. Opin. Crit. Care 10: 476-482. Harpur, E., D. Ennulat, D. Hoffman, G. Betton, J. C. Gautier, B. Riefke, D. Bounous, K. Schuster, S. Beushausen, M. Guffroy, M. Shaw, E. Lock, S. Pettit, and HESI Committee on Biomarkers of Nephrotoxicity. 2011. Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat. Toxicologic. Sci. 122: 235-252. Hewitt, N. A., A. A. O'Connor, D. V. O'Shaughnessy, and G. J. Elder. 2013. Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 8(7): 1143-1149. Hida, M., Y. Aiba, S. Sawamura, N. Suzuki, T. Satoh, and Y. Koga. 1996. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 74: 349-355. Hyun, H. S., K. H. Paik, and H. Y. Cho. 2013. p-Cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis. Korean J. Pediatr. 56(4): 159-164. Israni, A. K., and B. L. Kasiske. 2012. Laboratory assessment of kidney disease: glomerular filtration rate, urinalysis, and proteinuria. Pages 868-896 in Brenner and Rector's The Kidney, 9th ed. M. W. Taal et al. ed. W. B. Sauders, MO, USA. Iwata, K., H. Watanabe, T. Morisaki, T. Matsuzaki, T. Ohmura, A. Hamada, and H. Saito. 2007. Involvement of indoxyl sulfate in renal and central nervous system toxicities during cisplatin-induced acute renal failure. Pharm. Res. 24(4): 662-671. Jourde-Chiche, N., L. Dou, C. Cerini, F. Dignat-George, R. Vanholder, and P. Brunet. 2009. Protein-bound toxins-update. Sem. Dial. 22: 334-339. Kadam, K. L., and M. M. Newman. 1997. Development of a low-cost fermentation medium for ethanol production from biomass. Appl. Microbiol. Biotechnol. 47(6): 625-629. Koriem, K. M., M. S. Arbid, and K. R. Emam. 2014. Therapeutic effect of pectin on octylphenol induced kidney dysfunction, oxidative stress and apoptosis in rats. Environ. Toxicol. Pharmacol. 38(1): 14-23. Kusumoto, M., H. Kamobayashi, D. Sato, M. Komori, M. Yoshimura, A. Hamada, Y. Kohda, K. Tomita, and H. Saito. 2011. Alleviation of cisplatin-induced acute kidney injury using phytochemical polyphenols is accompanied by reduced accumulation of indoxyl sulfate in rats. Clin. Exp. Nephrol. 15: 820-830. Lee, P.C., W. G., Lee, S. Y. Lee, H. N.Chang, and Y. K., Chang. 2000. Fermentative production of succinic acid from glucose and corn steep liquor by Anaerobiospirillum succiniciproducens. Biotechnol. Bioprocess. Eng. 5: 379-381. Leung, K. C., M. Tonelli, and M. T. James. 2013. Chronic kidney disease following acute kidney injury-risk and outcomes. Nature Reviews Nephrol. 9: 77-85. Lieske, J. C., D. S. Goldfarb, C. de Simone, and C. Regnier. 2005. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int. 68: 1244-1249. Lilly, D., M. and R. H. Stillwell. 1965. Probiotics: growth promoting factors produced by microorganisms. Science 147: 747-748. Lind, E., J. Goldin, and J. Hickman. 1960. Fitting yield and cost response surface. Chem. Eng. Prog. 56: 62-68. Ling, W. H., R. Korpela, H. Mykkanen, S. Salminen, and O. Hanninen. 1994. Lactobacillus strain GG supplementation decreases colonic hydrolytic and reductive enzyme activities in healthy female adults. J. Nutr. 124(1): 18-23. Ma, Y., T. M. Curran, and R. E. Marquis. 1997. Rapid procedure for acid adaptation of oral lactic-acid bacteria and further characterization of the response. Can. J. Microbiol. 43(2): 143-148. Massart, A., F. D. Debelle, J. Racape, C. Gervy, C. Husson, M. Dhaene, K. M. Wissing, and J. L. Nortier. 2014. Biochemical parameters after cholecalciferol repletion in hemodialysis: Results from the VitaDial randomized trial. Am. J. Kidney Dis. In Press. Mazloom, Z., A. Yousefinejad, M. H. Dabbaghmanesh. 2013. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. Iran. J. Med. Sci. 38(1): 38-43. Meijers, B. K., and P. Evenepoel. 2011. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol. Dial. Transplant. 26: 759-761. Meijers, B. K., V. De Preter, K. Verbeke, Y. Vanrenterghem, and P. Evenepoel. 2010. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol. Dial. Transplant. 25: 219-224. Meyer, T. W., E. C. Leeper, D. W. Bartlett, T. A. Depner, Y. Zhao Lit, C. R. Robertson. and T. H. Hostetter. 2004. Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes. J. Am. Soc. Nephrol. 15: 1927-1935. Morisaki, T., T. Matsuzaki, K. Yokoo, M. Kusumoto, K. Iwata, A. Hamada, and H. Saito. 2008. Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats. Pharm. Res. 25: 2526-2533. Motojima, M., A. Hosokawa, H. Yamato, T. Muraki, and T. Yoshioka. 2002. Uraemic toxins induce proximal tubular injury via organic anion transporter 1-mediated uptake. Br. J. Pharmacol. 135: 555-563. Muteliefu, G., A. Enomoto, P. Jiang, M. Takahashi, and T. Niwa. 2009. Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol. Dial. Transplant. 24(7): 2051-2058. Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (eds). 1995. Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D. C. Nigatu, A. 2000. Evaluation of numerical analyses of RAPD and API 50 CH patterns to differentiate Lactobacillus plantarum, Lact. fermentum, Lact. rhamnosus, Lact. sake, Lact. parabuchneri, Lact. gallinarum, Lact. casei, Weissella minor and related taxa isolated from kocho and tef. J. Appl. Microbiol. 89(6): 969-978. Niwa, T. 2010. Indoxyl sulfate is a nephro-vascular toxin. J. Ren. Nutr. 20(5):2-6. Niwa, T., and M. Ise. 1994. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J. Lab. Clin. Med. 124: 96-104. Niwa, T., T. Miyazaki, N. Hashimoto, H. Hayashi, M. Ise, Y. Uehara, and K. Maeda. 1992. Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats. Am. J. Nephrol. 12(4): 201-206. Niwa, T., T. Nomura, S. Sugiyama, T. Miyazaki, S. Tsukushi, and S. Tsutsui. 1997. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int. 52: 23-28. Nowak, A., and Z. Libudzisz. 2007. Ability of intestinal lactic acid bacteria to bind or/and metabolise phenol and p-cresol. Ann. Microbiol. 57: 329-335. Pabla, N., and Z. Dong. 2008. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 73(9): 994-1007. Palipoch, S., and C. Punsawad. 2013. Biochemical and histological study of rat liver and kidney injury induced by cisplatin. J. Toxicol. Pathol. 26(3): 293-299. Parker, R. B. 1974. Probiotics, the other half of the antibiotic story. Anim. Nutr. Health. 29: 4-8. Perumalsamy, H., M. Y. Jung, S. M. Hong, and Y. J. Ahn. 2013. Growth-Inhibiting and morphostructural effects of constituents identified in Asarum heterotropoides root on human intestinal bacteria. BMC Complement Altern. Med. 13:245. Poesen, R., B. Meijers, and P. Evenepoel. 2013. The colon: an overlooked site for therapeutics in dialysis patients. Sem. Dial. 26(3): 323-32. Polak-Berecka, M., A. Waśko, M. Kordowska-Wiater, Z. Targoński, and A. Kubik-Komar. 2011. Application of response surface methodology to enhancement of biomass production by Lactobacillus rhamnosus E/N. Braz. J. Microbiol. 42(4): 1485-1494. Reagan-Shaw, S., M. Nihal, and N. Ahmad. 2007. Dose translation from animal to human studies revisited. FASEB J. 22(3):659-61. Sabbisetti, V., and J. V. Bonventre. 2012. Biomarkers in acute and chronic kidney diseases. Pages 1016-1042 in Brenner and Rector's The Kidney, 9th ed. M. W. Taal et al. ed. W. B. Sauders, MO, USA. Schaafsma, G. 1996. State of the art concerning probiotic strains in milk products. IDF Nutri. News. 5: 23-24. Shah, S. V., R. Baliga, M. Rajapurkar, and V. A. Fonseca. 2007. Oxidants in Chronic Kidney Disease. J. Am. Soc. Nephrol. 18(1):16-28. Shimizu, H., S. Saito, Y. Higashiyama, F. Nishijima, and T. Niwa. 2013. CREB, NF-κB, and NADPH oxidase coordinately upregulate indoxyl sulfate-induced angiotensinogen expression in proximal tubular cells. Am. J. Physiol. Cell. Physiol. 304(7): C685-692. Silveira, M. N., E. Wisbeck, I. Hoch, and R. Jonas. 2001. Production of glucose–fructose oxidoreductase and ethanol by Zimomonas mobilis ATCC 29191 in medium containing corn steep liquor as a source of vitamins. Appl. Microbiol. Biotechnol. 55: 442-445. Steckse’n-Blicks, C., I. Sjo‥ stro‥m, and S. Twetman. 2009. Effect of long-term consumption of milk supplemented with probiotic Lactobacilli and fluoride on dental caries and general health in preschool children: A cluster-randomized study. Caries Res. 43: 374-381. Takayama, F., K. Taki, and T. Niwa. 2003. Bifidobacterium in gastroresistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am. J. Kidney Dis. 41: S142-S145. Taki, K., F. Takayama, and T. Niwa. 2005. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J. Ren. Nutr. 15: 77-80. Tumur, Z., H. Shimizu, A. Enomoto, H. Miyazaki, T. Niwa. 2010. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am. J. Nephrol. 31: 435-441. Vanholder, R., and R. de Smet. 1999. Pathophysiologic effects of uremic retention solutes. J. Am. Soc. Nephrol. 10(8): 1815-1823. Vanholder, R., R. de Smet, G. Glorieux, A. Argiles, U. Baurmeister, P. Brunet, W. Clark, G. Cohen, P. P. de Deyn, R. Deppisch, B. Descamps-Latscha, T. Henle, A. Jorres, H. D. Lemke, Z. A. Massy, J. Passlick-Deetjen, M. Rodriguez, B. Stegmayr, P. Stenvinkel, C. Tetta, C. Wanner, W. Zidek and European Uremic Toxin Work Group (EUTox). 2003. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 63: 1934-1943. Widoff, W. R., A. T. Anfora, J. Liu, P. G. Schultz, S. A. Lesley,E. C.Peters, E. C., and G. Siuzdak. 2009. Metabolomics analysis reveals large effects of gut microflora on mammalian bold metabolities. Proc. of Natl. Acad. Sci. 106: 3698–3703. Yang, E. J., and H. C. Chang. 2010. Purification of a new antifungal compound produced by Lactobacillus plantarum AF1 isolated from kimchi. Int. J. Food Microbiol., 139: 56–63. Zhang, J. G., M. Viale, M. Esposito, and W. E. Lindup. 1999. Tiopronin protects against the nephrotoxicity of cisplatin in the rat. Hum. Exp. Toxic. 18(12): 713-717. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56993 | - |
dc.description.abstract | 硫酸吲哚酚為累積於慢性腎臟疾病患者體內之尿毒素之一,其親蛋白質的特性使此類尿毒素難以藉血液透析治療有效被去除,可能導致嚴重的腎功能衰退及心血管疾病等併發症,甚至造成死亡。吲哚為硫酸吲哚酚之前驅物,由可產生色胺酸酶之腸道細菌如 Escherichia coli等代謝色胺酸於腸道生成,再由肝臟代謝形成硫酸吲哚酚。本研究之目的為篩選具降低硫酸吲哚酚潛力之益生菌並探討其對血液硫酸吲哚酚濃度、腎功能及腸道菌組成影響及可能之機制。
首先經體外及動物試驗篩選出混合3株乳酸菌之Pm-1(Lactobacillus plantarum、 L. paracasei 及 Streptococcus thermophilus)較單一菌株更具有良好之硫酸吲哚酚移除潛力。動物試驗利用腹腔注射cisplatin誘導之急性腎損傷之大鼠模式探討Pm-1降低尿毒素之潛力,結果發現,餵食Pm-1之大鼠處理組可顯著降低cisplatin造成之血液中硫酸吲哚酚濃度升高及顯著降低腸道中之E. coli菌數,然而於腎功能相關之血液生化值則無顯著影響。 為了降低大量發酵之成本,本研究利用反應曲面法開發Pm-1共同最適化之取代培養基,以序列二次規劃法(sequential quadratic programming, SQP)進行最適化,經過氮、碳源篩選及反應曲面之建立等步驟,顯示使用糖蜜酵母粉,麥芽糊精及磷酸氫二鉀作為取代培養基之主原料配方可使所培養之菌數分別達到 9.01、8.71及8.94 log/mL,並且僅為商業培養基MRS成本之20%。 本研究亦比較延長餵食Pm-1之天數對cisplatin誘導之急性腎損傷大鼠模式之影響,結果顯示,藉由長期餵食 Pm-1 之試驗組中,其降低血液與肝、腎之硫酸吲哚酚濃度之能力較佳,根據實驗結果推測Pm-1可能藉由吸附或代謝腸道中之尿毒素前驅物、調控腸道菌組成及降低氧化壓力之機制而具有預防腎功能衰退之潛力。 | zh_TW |
dc.description.abstract | Numerous molecules that are either excreted or metabolized by the kidney accumulated in patients with chronic kidney disease (CKD). Indoxyl sulfate (IS) is a protein bound uremic toxin, which is unable to effectively eliminate by haemodialysis (HD). The accumulation of protein-bound uremic toxins has been suggested to be related to complications and mortality in HD patients. Indole, the precursor of IS, are produced by intestinal bacteria, such as Escherichia coli, from tryptophan. Since uremic toxins might be reduced by modulating microbiota in the colon, probiotics seem to be potential to reduce the concentration of intestinal nitrogenous metabolites. Thus, the aim of this study was to find potential probiotics which may improve renal function by reducing IS production.
Three strains, Lactobacillus plantarum, L. paracasei and Streptococcus thermophilus, were selected to have the ability to reduce indoxyl sulphate in vitro. Combination of strains (Pm-1) demonstrated a better IS removing ability than individual strains. We further investigated the uremic toxin-reducing probiotics by the cisplatin-induced acute kidney injury (AKI) rat model. Results indicated that oral administration of Pm-1 in cisplatin-induced acute kidney injury model significantly suppressed the accumulation of IS in the serum. Oral administration of Pm-1 also decreased in the number of E. coli and coliforms in feces. We further optimized growth medium by response surface methodology (RSM) with sequential quadratic programming (SQP). Results indicated that the media with sugar yeast, maltodextrin and dipotassium as major component could yield the highest cell numbers to 9.01、8.71 and 8.94 log/mL, respectively. The cost of medium was reduced to less than 20% when compared with commercial MRS medium. Our findings suggest that long term treatment with the strain combination Pm-1 might be a useful approach to decreasing IS accumulation in the serum and kidney. The possible mechanisms involved might include the binding/metabolizing IS in intestine and/or the modulation of bacterial growth in colon by Pm-1, both of which could decrease IS accumulation. The stimulation of anti-inflammatory cytokines and release of oxidative stress by Pm-1 might also be involved in the amelioration of AKI symptoms. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T06:32:33Z (GMT). No. of bitstreams: 1 ntu-103-R01626020-1.pdf: 2301249 bytes, checksum: c8b90b56ade8680f6d88a975d62df5ba (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 目錄
謝誌 i 序言 iii 中文摘要 iv 英文摘要 v 壹 文獻檢討 1 一、腎臟疾病與尿毒素之關係 1 (一)腎臟疾病 1 (二)腎臟疾病之評估與防治 2 (三)尿毒素─硫酸吲哚酚 3 二、順鉑之腎毒性與氧化壓力 7 三、益生菌降低血中硫酸吲哚酚 9 四、益生菌培養基之最適化開發 11 貳 材料與方法 12 一、實驗材料 13 (一)益生菌株 13 (二)試驗動物 13 (三)培養基 13 (四)凍乾保護劑 14 (五)試藥 14 (六)儀器 14 二、實驗方法 14 (一)潛力益生菌株之篩選 15 (二)Cisplatin 誘發急性腎損傷之治療模式 16 (三)菌株鑑定 18 (四)乳酸菌之酸適應與酸、膽鹽耐受性 21 (五)最適化取代培養基之尋求 21 (六)Cisplatin 誘發急性腎損傷之預防模式 25 (七)統計分析 27 參 結果與討論 28 第一節:具清除尿毒素硫酸吲哚酚潛力益生菌株篩選及鑑定 28 一、體外清除率 28 二、Cisplatin誘導急性腎損傷之治療模式 31 (一)大鼠血清及尿液IS 31 (二)大鼠臟器IS 31 (三)大鼠血液生化值 32 (四)腎臟組織切片 39 三、菌株鑑定與菌體型態觀察 43 第二節:菌株酸適應及最適化培養基之開發 46 一、酸適應與耐酸耐膽鹽 46 二、培養基最適化開發 52 第三節:動物試驗之預防模式 68 一、Cisplatin誘導急性腎損傷之預防模式 68 (一)大鼠血清IS 68 (二)大鼠臟器IS 68 (三)大鼠血液生化值 69 (四)組織切片圖 74 第四節:可能機制探討 78 一、糞便菌數 78 二、血清脂質過氧化物 78 肆 結論 82 參考文獻 83 | |
dc.language.iso | zh-TW | |
dc.title | 潛力益生菌株降低尿毒素硫酸吲哚酚於順鉑誘發急性腎損傷大鼠之研究 | zh_TW |
dc.title | Effect of potential probiotics on reducing uremic toxin indoxyl sulfate using the cisplatin-induced acute kidney injury rat model | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林慶文(Ching-Wen Lin),黃英豪(Ying-Hao Huang),劉?睿(Che-Jui Liu),李雅珍(Ya-Chen Li) | |
dc.subject.keyword | 慢性腎臟疾病,硫酸??酚,益生菌,反應曲面法, | zh_TW |
dc.subject.keyword | Chronic kidney disease,indoxyl sulfate,probiotics,response surface methodology, | en |
dc.relation.page | 93 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-08-05 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 動物科學技術學研究所 | zh_TW |
Appears in Collections: | 動物科學技術學系 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
ntu-103-1.pdf Restricted Access | 2.25 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.